Johnson & Johnson is in advanced talks to pay $2.3 billion in cash for the portion of Dutch vaccine maker Crucell that it doesn't already own in a bid to increase its foothold in vaccines.
WSJ.com: What's News US, Wall Street Journal
Fri, 09/17/2010 - 6:14pm
Johnson & Johnson is in advanced talks to pay $2.3 billion in cash for the portion of Dutch vaccine maker Crucell that it doesn't already own in a bid to increase its foothold in vaccines.